We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer ID6589 Consultation on suggested remit, draft scope and provisional ...
Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancer TA1138 2 March 2026 2 March 2026 ...
A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy ...
Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results